Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 7.61% is 58% below its 5-year average of 18.29%, around the middle of its 5-year range (-18.44%–34.69%).
163.12% above its 12-month average of 2.89%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -14.71%.
EBITDA MARGIN
7.61%
EBITDA MARGIN AVG TTM
2.89%
EBITDA MARGIN AVG 3Y
16.78%
EBITDA MARGIN AVG 5Y
18.29%
EBITDA MARGIN AVG 10Y
25.61%
EBITDA MARGIN AVG 15Y
23.59%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+163.12%
CURRENT VS 3Y AVG
-54.64%
CURRENT VS 5Y AVG
-58.38%
CURRENT VS 10Y AVG
-70.29%
CURRENT VS 15Y AVG
-67.74%
CURRENT VS 20Y AVG
N/A
Supernus Pharmaceuticals, Inc.
Market Cap
$2.47B
EBITDA Margin
7.61%
TTM Avg
2.89%
3Y Avg
16.78%
5Y Avg
18.29%
Market Cap
$2.41B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
Market Cap
$2.38B
EBITDA Margin
-4.36%
TTM Avg
-3.80%
3Y Avg
-12.43%
5Y Avg
-17.77%
Market Cap
$2.56B
EBITDA Margin
2.08%
TTM Avg
1.74%
3Y Avg
1.01%
5Y Avg
-2.48%
Market Cap
$2.60B
EBITDA Margin
-1001.92%
TTM Avg
-694.29%
3Y Avg
-672.56%
5Y Avg
-672.56%
Market Cap
$2.36B
EBITDA Margin
39.11%
TTM Avg
36.80%
3Y Avg
16.06%
5Y Avg
-24.25%
Market Cap
$2.35B
EBITDA Margin
-317.71%
TTM Avg
-346.77%
3Y Avg
-338.06%
5Y Avg
-349.04%
Market Cap
$2.35B
EBITDA Margin
19.20%
TTM Avg
19.07%
3Y Avg
18.61%
5Y Avg
17.12%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | $2.47B | 7.61% | 2.89% | 16.78% | 18.29% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.41B | -755.79% | -753.93% | -709.93% | -1157.85% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | -4.36% | -3.80% | -12.43% | -17.77% |
| Privia Health Group, Inc. (PRVA)vs › | $2.56B | 2.08% | 1.74% | 1.01% | -2.48% |
| Disc Medicine, Inc. (IRON)vs › | $2.37B | N/A | N/A | N/A | N/A |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.60B | -1001.92% | -694.29% | -672.56% | -672.56% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 39.11% | 36.80% | 16.06% | -24.25% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | -317.71% | -346.77% | -338.06% | -349.04% |
| UFP Technologies, Inc. (UFPT)vs › | $2.35B | 19.20% | 19.07% | 18.61% | 17.12% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.60B | -270.04% | -444.88% | -365.27% | -89273.54% |
Gross Margin
88.1%
EBITDA Margin
7.6%
Operating Margin
-5.1%
Net Margin
-13.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -14.71% |
| 2026-03-31 | 9.00% |
| 2025-12-31 | 18.36% |
| 2025-09-30 | -18.44% |
| 2025-06-30 | 20.25% |
| 2025-03-31 | 6.76% |
| 2024-12-31 | 23.11% |
| 2024-09-30 | 34.69% |
| 2024-06-30 | 25.72% |
| 2024-03-31 | 12.25% |
| 2023-12-31 | 12.59% |
| 2023-09-30 | 19.49% |
| 2023-06-30 | 2.31% |
| 2023-03-31 | 16.76% |
| 2022-12-31 | 32.98% |
| 2022-09-30 | 11.42% |
| 2022-06-30 | 19.35% |
| 2022-03-31 | 15.30% |
| 2021-12-31 | 11.82% |
| 2021-09-30 | 26.46% |
| 2021-06-30 | 28.82% |
| 2021-03-31 | 15.13% |
| 2020-12-31 | 33.80% |
| 2020-09-30 | 41.24% |
| 2020-06-30 | 38.34% |
| 2020-03-31 | 32.37% |
| 2019-12-31 | 42.26% |
| 2019-09-30 | 40.54% |
| 2019-06-30 | 42.29% |
| 2019-03-31 | 31.71% |
| 2018-12-31 | 35.84% |
| 2018-09-30 | 38.21% |
| 2018-06-30 | 37.67% |
| 2018-03-31 | 36.60% |
| 2017-12-31 | 40.72% |
| 2017-09-30 | 33.23% |
| 2017-06-30 | 36.15% |
| 2017-03-31 | 30.44% |
| 2016-12-31 | 27.20% |
| 2016-09-30 | 36.00% |
| 2016-06-30 | 22.07% |
| 2016-03-31 | 13.34% |
| 2015-12-31 | 16.69% |
| 2015-09-30 | 11.74% |
| 2015-06-30 | 9.39% |
| 2015-03-31 | 12.95% |
| 2014-12-31 | 16.09% |
| 2014-09-30 | 56.03% |
| 2014-06-30 | 13.44% |
| 2014-03-31 | -145.30% |
| 2013-12-31 | -107.81% |
| 2013-09-30 | -1350.44% |
| 2013-06-30 | -5450.18% |
| 2013-03-31 | -12072.11% |
| 2012-12-31 | -1148.90% |
| 2012-09-30 | -13272.53% |
| 2012-06-30 | -9938.46% |
| 2012-03-31 | -3679.33% |
| 2011-12-31 | 202.15% |
| 2011-09-30 | -88100.00% |
| 2011-06-30 | -1090.27% |
| 2010-12-31 | 221.29% |
| 2009-12-31 | 261.88% |
